BEGIN:VCALENDAR
PRODID:-//Columba Systems Ltd//NONSGML CPNG/SpringViewer/ICal Output/3.3-
 M3//EN
VERSION:2.0
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
DTSTAMP:20260921T165556Z
DTSTART:20261019T130000Z
SUMMARY:DCS and MBC Joint Seminar: TONI CELIÀ-TERRASSA "LCOR implications
  in breast cancer immunity and therapeutic opportunities"
UID:{http://www.columbasystems.com/customers/uom/gpp/eventid/}b5a-mubhlbd
 9-lv4r0a
DESCRIPTION:Division of Cancer Sciences (DCS) and Manchester Breast Centr
 e (MBC) Joint Seminar\nDr Toni Celia-Terrassa\nCancer Cell States & Meta
 stasis Immunity Lab at the Hospital del Mar Research Institute\, Barcelo
 na\, Spain\nTitle: LCOR implications in breast cancer immunity and thera
 peutic opportunities.\nHost: Bruno Simões\nDate: Monday 19th October 202
 6\nTime: 2pm\nVenue: Oglesby Cancer Research Building\, 555 Wilmslow Rd\
 , Manchester M20 4GJ\n\nTONI CELIÀ-TERRASSA\, PHD.\nGroup Leader of the 
 Cancer Cell States & Metastasis Immunity Lab at the Hospital del Mar Res
 earch Institute (HMRI). His scientific career is driven by a central obj
 ective: to understand how cancer cell-state plasticity and immune survei
 llance shape breast cancer metastasis\, and how these principles can be 
 therapeutically exploited.\nHe obtained his PhD in 2012 at the IBMB-CSIC
  / University of Barcelona under the supervision of Dr. Timothy Thomson\
 , where his doctoral work provided paradigm-shifting insights into epith
 elial-to-mesenchymal transition (EMT) plasticity\, revealing how embryon
 ic stem cell–like programs and their reversion govern metastatic compete
 nce and colonization. He then pursued postdoctoral training (2012–2017) 
 at Princeton University in the laboratory of Dr. Yibin Kang\, a world le
 ader in breast cancer metastasis research. During more than five years a
 t Princeton\, he specialized in mammary stem cell programs driving metas
 tasis and uncovered mechanisms by which normal and malignant stem cells 
 evade immune surveillance\, elucidating the spatiotemporal dynamics of E
 MT–MET transitions within the metastatic microenvironment.\nSince establ
 ishing his independent group in 2018\, the lab integrates cancer cell-st
 ate dynamics\, stem cell biology\, and tumor immunology to develop innov
 ative immunotherapeutic and immunopreventive strategies. The group has c
 ontributed key conceptual advances\, including the identification of imm
 une-evasive cancer stem cell states\, the distinctive immunology of micr
 ometastasis\, and the demonstration that mRNA-based therapies can be use
 d to therapeutically modulate cancer cell states.\nhttps://celiaterrassa
 lab.com/ [celiaterrassalab.com]\n\nRecent publications:\nJCI - Estrogen 
 receptor signaling drives immune evasion and immunotherapy resistance in
  HR+ breast cancer\nTIM3+ breast cancer cells license immune evasion dur
 ing micrometastasis outbreak: Cancer Cell\nLCOR mediates interferon-inde
 pendent tumor immunogenicity and responsiveness to immune-checkpoint blo
 ckade in triple-negative breast cancer | Nature Cancer\n\n
STATUS:TENTATIVE
TRANSP:TRANSPARENT
CLASS:PUBLIC
LOCATION:Oglesby Cancer Research Building\, 555 Wilmslow Rd\, Manchester\
 , M20 4GJ
END:VEVENT
END:VCALENDAR